T-cell dysfunction has been shown to play an important role in the pathogenesis of Sjögren’s syndrome (SS). In recent studies, the increased expression of BMP6 has been reported to be related to SS. However, the roles that BMP6 plays in immune homeostasis in the development of SS as well as the downstream signals activated by BMP6 remain unclear. In this study, we investigated the effects and molecular mechanisms of BMP6 on naive CD4+ T cells, showing that BMP6 could upregulate interferon (IFN)–γ secretion from CD4+ T cells through a ceramide/nuclear factor–κB pathway, with no effect on T-cell activation or proliferation. Moreover, an in vivo study showed that anticeramide treatment (myriocin) for an SS animal model (NOD/LtJ mice) could significantly decrease the IFN-γ expression and Th1 frequency in the salivary glands and suppress the inflammation infiltration in salivary glands and maintain the salivary flow rates, both of which reflect SS-like symptoms. This study identifies a promising target that could effectively attenuate the abnormal state of CD4+ T cells and reverse the progression of SS.
AdamsonTCIIIFoxRIFrismanDMHowellFV. 1983. Immunohistologic analysis of lymphoid infiltrates in primary Sjögren’s syndrome using monoclonal antibodies. J Immunol. 130(1):203–208.
2.
AluriHSSamizadehMEdmanMCHawleyDRArmaosHLJangaSRMengZSendraVGHamrahPKublinCL, et al. 2017. Delivery of bone marrow-derived mesenchymal stem cells improves tear production in a mouse model of Sjögren’s syndrome. Stem Cells Int. 2017:3134543.
3.
BallouLRLaulederkindSJRosloniecEFRaghowR. 1996. Ceramide signalling and the immune response. Biochim Biophys Acta. 1301(3):273–287.
4.
BatallerMSanchez-GarciaAGarcia-MayeaYMirCRodriguezIMELL. 2021. The role of sphingolipids metabolism in cancer drug resistance. Front Oncol. 11:807636.
5.
BrandtJEPrioriRValesiniGFairweatherD. 2015. Sex differences in Sjögren’s syndrome: a comprehensive review of immune mechanisms. Biol Sex Differ. 6:19.
6.
CastroBMPrietoMSilvaLC. 2014. Ceramide: a simple sphingolipid with unique biophysical properties. Prog Lipid Res. 54:53–67.
7.
ChenXAqrawiLAUtheimTPTashbayevBUtheimOAReppeSHoveLHHerlofsonBBSinghPBPalmO, et al. 2019. Elevated cytokine levels in tears and saliva of patients with primary Sjögren’s syndrome correlate with clinical ocular and oral manifestations. Sci Rep. 9(1):7319.
8.
D’AgostinoCElkashtyOAChivassoCPerretJTranSDDelporteC. 2020. Insight into salivary gland aquaporins. Cells. 9(6):1547.
FuJPuYWangBLiHYangXXieLShiHWangZYinJZhanT, et al. 2022. Pharmacological inhibition of glutaminase 1 normalized the metabolic state and CD4+ T cell response in Sjögren’s syndrome.J Immunol Res. 2022:3210200.
13.
GençDGünaydinBSezginSAladağATarhanEF. 2022. Immunoregulatory effects of dental mesenchymal stem cells on T and B lymphocyte responses in primary Sjögren’s syndrome. Immunotherapy. 14(4):225–247.
14.
GroschSAlessenkoAVAlbiE. 2018. The many facets of sphingolipids in the specific phases of acute inflammatory response. Mediators Inflamm. 2018:5378284.
15.
HannunYAObeidLM. 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 9(2):139–150.
16.
HannunYAObeidLM. 2018. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 19(3):175–191.
17.
HarrisVKStarkJVyshkinaTBlackshearLJooGStefanovaVSaraGSadiqSA. 2018. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine. 29:23–30.
18.
KakoiHironoriMaedaShingoShinoharaNaohiroMatsuyamaKanehiroImamuraKatsuyukiKawamuraIchiroNaganoSatoshiSetoguchiTakaoYokouchiMasahiroIshidouYasuhiro, et al. 2014. Bone Morphogenic Protein (BMP) Signaling Up-regulates Neutral Sphingomyelinase 2 to Suppress Chondrocyte Maturation via the Akt Protein Signaling Pathway as a Negative Feedback Mechanism. J Biol Chem. 289(12):8135–8150.
19.
JinJOYuQ. 2013. T cell-associated cytokines in the pathogenesis of Sjögren’s syndrome. J Clin Cell Immunol. S1(9):11742. doi:10.4172/2155-9899.S1-009
20.
KatsifisGEMoutsopoulosNMWahlSM. 2007. T lymphocytes in Sjögren’s syndrome: contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol. 32(3):252–264.
21.
KueCSJungMYChoDKimTS. 2012. C6-ceramide enhances Interleukin-12-mediated T helper type 1 cell responses through a cyclooxygenase-2-dependent pathway. Immunobiology. 217(6):601–609.
22.
LaiZYinHCabrera-PerezJGuimaroMCAfioneSMichaelDGGlentonPPatelASwaimWDZhengC, et al. 2016. Aquaporin gene therapy corrects Sjögren’s syndrome phenotype in mice. Proc Natl Acad Sci U S A. 113(20):5694–5699.
23.
LauritsenJPChristensenMDDietrichJKastrupJOdumNGeislerC. 1998. Two distinct pathways exist for down-regulation of the TCR. J Immunol. 161(1):260–267.
24.
MaeharaTMoriyamaMHayashidaJNTanakaAShinozakiSKuboYMatsumuraKNakamuraS. 2012. Selective localization of T helper subsets in labial salivary glands from primary Sjögren’s syndrome patients. Clin Exp Immunol. 169(2):89–99.
25.
Matsumura-KawashimaMOgataKMoriyamaMMurakamiYKawadoTNakamuraS. 2021. Secreted factors from dental pulp stem cells improve Sjögren’s syndrome via regulatory T cell-mediated immunosuppression. Stem Cell Res Ther. 12(1):182.
26.
MatsumuraRUmemiyaKGotoTNakazawaTOchiaiKKagamiMTomiokaHTanabeESugiyamaTSueishiM. 2000. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol. 18(3):311–318.
27.
MavraganiCPMoutsopoulosHM. 2020. Sjögren’s syndrome: old and new therapeutic targets. J Autoimmun. 110:102364.
28.
MelendezAJ. 2008. Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. Biochim Biophys Acta. 1784(1):66–75.
29.
MitsiasDITzioufasAGVeiopoulouCZintzarasETassiosIKKogopoulouOMoutsopoulosHMThyphronitisG. 2002. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren’s syndrome. Clin Exp Immunol. 128(3):562–568.
30.
NiesnerUAlbrechtIJankeMDoebisCLoddenkemperCLexbergMHEulenburgKKreherSKoeckJBaumgrassR, et al. 2008. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med. 205(8):1889–1901.
SinghNCohenPL. 2012. The T cell in Sjögren’s syndrome: force majeure, not spectateur. J Autoimmun. 39(3):229–233.
33.
SistoMRibattiDLisiS. 2021. SMADS-mediate molecular mechanisms in Sjögren’s syndrome. Int J Mol Sci. 22(6):3203.
34.
SuYGuYWuRWangH. 2018. Bone morphogenetic protein 6 inhibits the immunomodulatory property of BMMSCs via Id1 in Sjögren’s syndrome. Stem Cells Int. 2018:9837035.
35.
van WoerkomJMKruizeAAWenting-van WijkMJKnolEBihariICJacobsJWBijlsmaJWLafeberFPvan RoonJA. 2005. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren’s syndrome compared with non-Sjögren’s sicca syndrome. Ann Rheum Dis. 64(10):1474–1479.
36.
XuJSuYHuLCainAGuYLiuBWuRWangSWangH. 2018. Effect of bone morphogenetic protein 6 on immunomodulatory functions of salivary gland-derived mesenchymal stem cells in Sjögren’s syndrome. Stem Cells Dev. 27(22):1540–1548.
37.
YaoYMaJFChangCXuTGaoCYGershwinMELianZX. 2021. Immunobiology of T cells in Sjögren’s syndrome. Clin Rev Allergy Immunol. 60(1):111–131.
38.
YinHCabrera-PerezJLaiZMichaelDWellerMSwaimWDLiuXCatalanMARochaEMIsmailN, et al. 2013. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren’s syndrome and in mice. Arthritis Rheum. 65(12):3228–3238.
39.
YinHKalraLLaiZGuimaroMCAberLWarnerBMMichaelDZhangNCabrera-PerezJKarimA, et al. 2020. Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren’s syndrome in mice. Sci Rep. 10(1):2967.
40.
ZhanTWangBFuJShaoYYeLShiHZhengL. 2021. Artesunate inhibits Sjögren’s syndrome-like autoimmune responses and BAFF-induced B cell hyperactivation via TRAF6-mediated NF-κB signaling. Phytomedicine. 80:153381.
41.
ZhangYAlexanderPBWangXF. 2017. TGF-β family signaling in the control of cell proliferation and survival. Cold Spring Harb Perspect Biol. 9(4):a022145.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
